Cue Biopharma, Inc. · NASDAQ:CUE
Cue Biopharma — IPO Roadshow (December 2017)
18 slides from Cue Biopharma's IPO roadshow presentation, Dec 5, 2017
Slide 1: Immune Responses, On Cue – IPO Presentation
Immune Responses, On Cue IPO Presentation © Copyright 2017 Cue Biopharma TM . All rights reserved . Filed pursuant to Rule 433 Registration Statement No. 333 - 220550 December 5, 2017
Slide 2: THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC FOR
THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATI
Slide 3: Targeted Immune Modulation: The Future of Immunotherapy
Targeted Immune Modulation: The Future of Immunotherapy The Cue Biologics TM Platform: A Potentially Disruptive Breakthrough Technology Selective control of immune responses is key to safer and more effective immunotherapies addressing oncology and autoimmune diseases Most current approaches globall
Slide 4: Turning the Immune System On and Off
Turning the Immune System On and Off T cells are responsible for the bulk of the immune response to threats including cancer T Cell T Cell T Cell T Cell T Cell T Cell T Cell T Cell X Antigen Presenting Cell (APC) 2. Stimulatory Signal 1. Antigen Presentation 2. Inhibitory Signal 1. Antigen Presentat
Slide 5: An Engineering Solution to Targeted Immune Modulation
An Engineering Solution to Targeted Immune Modulation Modular design allows for versatility to address cancer and autoimmune diseases Fc CUE Biologic TM Framework Antigen Presentation (Highly targeted) Co - stimulatory ligand(s) (Activating/Inhibitory Signal) Antibody like format (Stability/Manufact
Slide 6: CUE Biologics for Targeted T-cell Modulation
CUE Biologics TM for Targeted T - cell Modulation • Biologic design platform to modulate specific T cell population - Injectable biologics mimic the natural APC signaling mechanism - One building block, multiple drug iterations • Pre - clinical data demonstrates specific immune response - Human tran
Slide 7: Modular Structure to Rapidly Generate Additional Drugs
Modular Structure to Rapidly Generate Additional Drugs Rapid validation for additional disease indications, e.g., multiple cancers • Expandable platform – develop framework first - Different antigens on validated framework creates new drugs - Rapid validation for additional disease indications • Exc
Slide 8: Human Ex Vivo Assays: A Potential Paradigm Shift in Drug Development
Human Ex Vivo Assays: A Potential Paradigm Shift in Drug Development Potentially powerful tool for demonstrating preclinical proof of mechanism and proof of concept + Extract Blood from Patients Isolate T cells Add Cue Biologic to T cells Assay Selective Activation and Expansion Traditional drug dis
Slide 9: Validating Drug Candidates for Cancer Through Ex Vivo Assays
Validating Drug Candidates for Cancer Through Ex Vivo Assays Potential candidates are assessed by four main metrics prior to selection E ngagement Assay Type : Direct cell binding, Receptor binding Clinically Informs : Specificity of binding, Receptor occupancy, PK/PD model of safety and efficacy E
Slide 10: CUE-101 is Exemplary of Our Approach in Oncology
CUE - 101 is Exemplary of Our Approach in Oncology Rationale • HPV+ cancers affect ~25,000 Americans annually • E7 protein is a tumor specific driver of oncogenesis and the epitope is highly immunogenic • Therapeutic profile of IL - 2 is well characterized and familiar to regulatory agencies and phy
Slide 11: Developing CUE Biologic Frameworks for Autoimmune Diseases
Developing CUE Biologic Frameworks for Autoimmune Diseases Two potential mechanisms of action Fc CUE Biologics TM MHC Class I CTL TCR Targeting Co - stimulatory ligand(s) (Inhibitory Signal) Fc CUE Biologics TM MHC Class II Treg TCR Targeting Co - stimulatory ligand(s) ( Treg Induction Signal) Direc
Slide 12: Our First Partnership Speeding Autoimmune Development
Our First Partnership Speeding Autoimmune Development Strategic Research Collaboration and License Agreement Agreement Focused on Development of Next - Generation Biologics to Selectively Modulate T Cell Activity for the Treatment of Autoimmune Diseases 12
Slide 13: Management Team
Management Team Dan Passeri , M.Sc., J.D. President and CEO Kenneth Pienta , M.D. Acting Chief Medical Officer Ronald D. Seidel III, Ph.D. Co - Founder and EVP, Head of R&D Rodolfo J. Chapparo , Ph.D. Co - Founder and EVP, Head of Immunology Mary Simcox , Ph.D. VP of Translational Biology 13
Slide 14: Independent Directors and Scientific Advisory Board
Independent Directors and Scientific Advisory Board Peter Kiener , Ph.D. – Chairman Current CSO at Sucampo Pharmaceuticals, Inc. Former CSO of Ambrx Inc., and President and Co - founder of Zyngenia Inc., Also held senior leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca. Bar
Slide 15: The IPO
The IPO • Between $40 - $60MM at $7.50 per share • Pre - Money Valuation Approximately $80MM based on 10.7MM shares outstanding pre - offering • Best Effort Offering – Subscription Form and Wire to Escrow Agent • Begin Trading on NASDAQ approximately 3 days after closing • Trading Symbol - CUE NASDA
Slide 16: Use of Proceeds
Use of Proceeds We believe the net proceeds from this offering will be sufficient to allow us to: • Complete IND - enabling studies for our lead product candidate, file such IND and initiate the Phase I trial for that candidate; • Identify, optimize and nominate one additional drug candidate for imm
Slide 17: Driving Value: Key Initiatives for 2018
Driving Value • Continue development of pipeline of CUE - 100 series • Further development and refinement of ex vivo assay capabilities • Develop proof of concept in auto - immune program with Merck • Complete IND - enabling studies for our lead product candidate, file IND and initiate Phase 1 trial
Slide 18: Thank You
Immune Responses, On Cue THANK YOU! www.cuebio.com © Copyright 2016 Cue Biopharma . All rights reserved .